TrimRx's Blog

Running out of semaglutide or tirzepatide between refills is more common than the FDA shortage status suggests.

Six-month tirzepatide weight loss averages roughly 12 to 18 percent of starting body weight at the higher maintenance doses (10 to 15 mg weekly).

Introduction Most people lose 5 to 10% of their starting body weight in the first 3 months on semaglutide, which translates to roughly 10…

Introduction First-month weight loss on GLP-1 medications typically ranges from 2 to 5 percent of starting body weight, which translates to roughly 4 to…

Wegovy does not produce chemical withdrawal. There is no shaking, no rebound anxiety from receptor adaptation, no seizure risk.

Wegovy is semaglutide 2.4 mg dosed once weekly for chronic weight management. The phase 3 STEP 1 trial (Wilding et al.

Wegovy and Zepbound are the two FDA-approved brand-name obesity medications dominating the market in 2026.

Sleep problems on Wegovy are real but mild for most people. The STEP 1 trial (Wilding et al.

The Wegovy shortage that began in 2022 was officially declared resolved by the FDA in February 2025.